We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors.
Global Anti-Diabetic Drugs Industry: Market Segmentation By Drug Class, By Mode of Administration, By Diabetes Type, By Drug Type & by Region with Forecast 2017-2030
Global Anti-Diabetic Drugs Market Overview
Antidiabetic drugs do not cure diabetes instead they help diabetic patients to keep their condition under control and lower the risk of diabetes complications in future. Type 2 diabetes and other non-communicable diseases are a major public health concern globally with 6.4% of the adult’s population i.e. 285 million people are suffering from diabetes, which is projected to reach the number 552 million by 2030, according to the International Diabetes Federation. In US alone approximating 79 million individuals are reported prediabetic. Most of the diabetic population prefers generic drugs rather than the branded ones, for instance, most people take metformin, not Glucophage, and similarly many take glipizide, a generic sulfonylurea drug, while few take Glucotrol, its brand-name version.
Goldstein Market Intelligence analyst forecast that antidiabetic drugs market size is growing at a CAGR of 10.12% through the forecast years of 2017-2030.
Global Anti-Diabetic Drugs Market Segmentation
By Drug Class
Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin)
α-Glucosidase inhibitors (acarbose)
By Mode of Administration
Oral (eg. oral hypoglycemic)
Intravenously (eg. insulin and GLP-1 receptor agonists)
By Diabetes Type
Diabetes Type 1
Diabetes Type 2
Genetic defects of the β-cell
Genetic defects in insulin action
Drug- or chemical-induced diabetes
Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)
By Drug Type
Based on Geography
North America (U.S. & Canada) Antidiabetic Drugs Market
Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Antidiabetic Drugs Market
Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) Antidiabetic Drugs Market
Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) Antidiabetic Drugs Market
Middle East & Africa (GCC, South Africa, North Africa, RoMEA) Antidiabetic Drugs Market
Revenue Share by Drug Type & by Region
On the basis of drug type, branded drugs dominate the antidiabetic drugs market by acquiring 51% of total market share while in future generic drugs tends to hold the promising market . According to our global market study on the basis of extensive primary and secondary research: “One of the growing trend of antidiabetic drugs market is that CRO (Contract Research Organizations) and CMO (Contract Manufacturing Organization) sectors saw dozens of acquisitions in 2016 and 2017, and expect that trend to continue in 2018.”
Based on geography, North America holds the largest market share of 35% in 2016 while APAC is projected to witness a robust growth with a CAGR of 11.12% over the forecast years 2017-2030. Middle East and Africa hold the opportunities for the antidiabetic drugs player owing to consumer spending capacity and rising irregular dietary habits leading to increasing occurrences of diabetes and related disorders
Drivers & Challenges to Market Growth
According to the report, major driver for expansion of Antidiabetic Drugs market is strong encouragement from the governments like promoting healthy nutritional policies and favoring modifications in the environment that encourage greater physical activity and make prevention affordable for all citizens at high risk are the drivers of antidiabetic drug market.
Further, the report states that one challenge in antidiabetic drug market is despite the availability of numerous branded antidiabetic drugs, maximum of them have lost patent protection and due to huge pressures from government and regulatory authorities, to ban top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients.
Covered in this Global Antidiabetic Drugs Market Report
The report covers the present ground scenario and the future growth prospects of the Antidiabetic Drugs market for 2017-2030 along with the number of diabetic population and adoption rate of generic as well as branded drugs. We calculated the market size and revenue share on the basis of revenue generated from the sales of Antidiabetic Drugs from major players and number of total diabetic patients across the globe.
Antidiabetic Drugs Market Outlook 2017-2030, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the global antidiabetic drugs market. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. Global market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.
Key Market Players
Our global antidiabetic drugs market report comprises of the following companies as the key players in the Antidiabetic Drugs market.
Other high-flying vendors in the market are Eli Lilly, Franco-Indian Pharmaceuticals, Furiex Pharmaceuticals, Genentech, Generex Biotechnology Corporation, GlaxoSmithKline (GSK), Johnson & Johnson (J&J), Lupin, Merck & Co., Mylan, Novartis, Novo Nordisk, Pfizer, Ranbaxy Laboratories, Roche, Sanofi, Sun Pharma
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.